Combination of Different Platinum Compounds: Issues, Strategies, and Experience

  • Franco M. Muggia


The rationale for combination of cisplatin and carboplatin is based primarily on 1) a steep dose-response in antitumor effects of platinums, and 2) the widely different dose-limiting toxicities for cisplatin and carboplatin. With the introduction of several new analogues, the rationale of lack of complete cross-resistance becomes increasingly attractive. In fact, both preclinical and clinical data have been assembled in support of the hypothesis that combinations of platinum compounds may lead to improved therapeutic effects. We review here the issues concerned with specific platinum combinations and illustrate possible strategies to test such combinations, and preliminary clinical experience.


Ovarian Cancer Germ Cell Tumor Platinum Compound Buccal Cell Dose Intensification 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D.T. Trump, J.L. Grem, K.D. Tutsch, J.K.V. Willson, K.J. Simon, D. Alberti, B. Storer, and D.C. Tormey. Platinum analogue combination chemotherapy: cisplatin and carboplatin — a Phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J. Clin. Oncol. 5:1281, (1987).PubMedGoogle Scholar
  2. 2.
    F.M. Muggia and I. Gill. Optimizing dose-intensity: combining carboplatin with cisplatin, in: “Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy”, S.B. Howell, ed., Plenum, New York (1991).Google Scholar
  3. 3.
    C. Sessa, A. Goldhirsch, G. Martinelli, M. Alerci, L. Imburgia, and F. Cavalli. Phase I study of the combination of monthly carboplatin and weekly cisplatin, Ann. Oncol 2:123(1991).CrossRefPubMedGoogle Scholar
  4. 4.
    K. Kobayashi, A. Yoshimura, M. Hino, A. Gemma, K. Yoshimori, M. Shibuya, T. Takemoto, K. Hayashihara, M. Matsuzaka, S. Wasai, and H. Niitani. Combination of cisplatin and carboplatin in vitro and in clinical practice, in: “Cancer Chemotherapy — Challenges for the Future”, Volume 8, edited by K. Kimura, H. Saito, S.K. Carter, and R.C. Bast, Jr., Excerpta Medica, Tokyo, 1992.Google Scholar
  5. 5.
    F.A. Blommaert, C. Michael, P.A.B. Terheggen, F.M. Muggia, V. Kortes, J.H. Schornagel, A.A.M. Hart, and L. den Engelse. Drug-induced DNA modification in buccal cells of cancer patients during carboplatin and cisplatin combination chemotherapy as determined by an immunocytochemical method: interindividual variations and correlation with disease response, Cancer Res 53:5669, (1994).Google Scholar
  6. 6.
    B. Uziely, S.C. Formenti, K. Watkins, A. Mazumder, and F.M. Muggia. Calvert’s formula and high-dose carboplatin, J. Clin. Oncol. 12:1740, (1994)PubMedGoogle Scholar
  7. 7.
    M.J. Piccart, J.M. Nogaret, L. Marcelis, H. Longree, F. Ries, J.P. Kainds, P. Gobert, A.M. Domage, J.P. Sculier, G. Gompel and the Belgian Study Group for Ovarian Carcinoma. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in treatment of ovarian cancer, J. Clin. Oncol. 2:1281(1987).Google Scholar
  8. 8.
    B. Lund, M. Hansen, O.P. Hansen, and H.H. Hansen. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease, J. Clin. Oncol. 7:1469 (1989).PubMedGoogle Scholar
  9. 9.
    B. Lund, M. Hansen, O.P. Hansen, and H.H. Hansen. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease, J. Clin. Oncol. 8:1226 (1990).PubMedGoogle Scholar
  10. 10.
    B. Lund, O.P. Hansen, H.H. Hansen, and M. Hansen. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Sem Oncol. 19(1):26 (1992).Google Scholar
  11. 11.
    J.R. Hardy, E. Wiltshaw, P.R. Blake, P. Harper, M. Slevin, T.J. Perrin, and S. Tan. Cisplatin and carboplatin in combination for the treatment of stage IV ovarian carcinoma. Ann. Oncol. 2:131 (1991).CrossRefPubMedGoogle Scholar
  12. 12.
    E. Reed (Personal communication).Google Scholar
  13. 13.
    G. Bolis (to be published, 1995).Google Scholar
  14. 14.
    F. Muggia, L. Muderspach, L. Roman, S. Jeffers, S. Groshen, P. Conti, S.E. Martin, and C.P. Morrow. Phase I/II study of intraperitoneal floxuridine (FUDR) with either cisplatin or carboplatin or both, Proc. Amer. Soc. Clin. Oncol. 14:(1995).Google Scholar
  15. 15.
    J.P. Caussavel, F. Levi, S. Brienza, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate, J. Natl. Cancer Inst. 82:1046, (1990)CrossRefGoogle Scholar
  16. 16.
    G. Mathe, E. Chenu, C. Bourut, et al. Experimental study of three platinum complexes: CDDP, CBDCA and l-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes, Proc. Amer. Assoc. Cancer Res. 30:1872(1989).Google Scholar
  17. 17.
    J.F. Llory, P. Soulie, E. Cvitkovic, and J.L. Misset. Feasibility of high-dose platinum delivery with combined carboplatin and oxaliplatin, J. Natl. Cancer Inst. 86:1098(1994).CrossRefPubMedGoogle Scholar
  18. 18.
    P. Soulie, E. Cvitkovic, C. Garrino, M. Frereres, K. Azzouzi, J.F. Llory, M. Musset, J. Gastiaburu, and J.L. Misset. Combined oxaliplatin (1-OHP) cisplatin: an effective approach to optimize platinum treatment of malignancies, Proc. Amer. Assoc. Cancer Res. 35:438 (1994).Google Scholar
  19. 19.
    E. Cvitkovic, M. Frereres, P. Soulie, J.F. Llory, O. Rixe, C. Garrino, M. Marty, and J.L. Misset. High activity in pretreated germ cell tumors of combined oxaliplatin (l-OHP) cisplatin based salvage regimen, Proc. Amer. Assoc. Cancer Res. 35:233 (1994).Google Scholar
  20. 20.
    J.L. Misset, P. Soulie, M. Frereres, J.F. Llory, E. Raymond, M. Musset, P. Chollet, C. Jasmin, C. Garrino, and E. Cvitkovic. High efficacy of combined oxaliplatin (l-OHP) cisplatin as salvage treatment in pretreated ovarian cancer, Proc. Amer. Assoc. Cancer Res. 35:234 (1994).Google Scholar
  21. 21.
    C. Garrino, E. Cvitkovic, P. Soulie, M. Frereres, E. Brain, S. Brienza, M. Itzhaki, C. Jasmin, and J.L. Misset. Toxicity patterns of the oxaliplatin/cisplatin association alone or with ifosfamide/epiadriamycin to platinum pretreated patients, Proc. Amer. Assoc. Cancer Res. 35:244 (1994).Google Scholar
  22. 22.
    J.A. Gietema, E.G. DeVries, D.T. Sleijfer, P.H. Willemse, H.J. Guchelaar, D.R. Uges, P. Aulenbacher, R. Voegeli, N.H. Mulder. A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. Brit. J. Cancer 67:396 (1993).CrossRefPubMedGoogle Scholar
  23. 23.
    M.J. McKeage, L.R. Kelland, F.E. Boxal, M.R. Valenti, M. Jones, P.M. Goddard, J. Gwynne, and K.R. Harrap. Schedule dependency of orally administered bis-acetato-amminedichloro-cyclohexylamine-platinum (IV) (JM216) in vivo, Cancer Res. 54:4118 (1994).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Franco M. Muggia
    • 1
  1. 1.Medical OncologyUSC-Norris Cancer CenterLos AngelesUSA

Personalised recommendations